The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Open accessAbstract
We examined the effect of three months of rosiglitazone treatment (4 mg b.i.d.) on whole-body insulin sensitivity and in vivo peripheral adipocyte insulin sensitivity as assessed by glycerol release in microdialysis from subcutaneous fat during a two-step (20 and 120 mU · m−2 · min−1) hyperinsulinemic-euglycemic clamp in nine type 2 diabetic subjects. In addition, the effects of rosiglitazone on liver and muscle triglyceride content were assessed by 1H-nuclear magnetic resonance spectroscopy. Rosiglitazone treatment resulted in a 68% (P < 0.002) and a 20% (P < 0.016) improvement in insulin-stimulated glucose metabolism during the low- and high- dosage−insulin clamps, respectively, which was associated with ∼40% reductions in plasma fatty acid concentration (P < 0.05) and hepatic triglyceride content (P < 0.05). These changes were associated with a 39% increase in extramyocellular lipid content (P < 0.05) and a 52% increase in the sensitivity of peripheral adipocytes to the inhibitory effects of insulin on lipolysis (P = 0.04). In conclusion, these results support the hypothesis that thiazolidinediones enhance insulin sensitivity in patients with type 2 diabetes by promoting increased insulin sensitivity in peripheral adipocytes, which results in lower plasma fatty acid concentrations and a redistribution of intracellular lipid from insulin responsive organs into peripheral adipocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies by our group (9, 17-20) and others (7, 21, 22) have demonstrated a strong relationship between triglyceride content in liver and muscle and insulin resistance in these tissues.”
From Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy (2002) · cites this paper as [9]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Though no reductions in the concentration of intramyocellular triglyceride were noted in this study, rosiglitazone improved insulin-mediated whole-body glucose disposal, consistent with improvements in muscle insulin sensitivity.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Treatment for 3 months with rosiglitazone was associated with an almost 40% reduction in hepatic triglyceride content, and roughly 40% increase in extramyocellular triglyceride concentration, and improved suppression of adipocyte lipolysis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Thiazolidinediones, which are potent PPARγ agonists, can effectively reduce hepatic steatosis.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Moreover, reductions in intracellular diacylglycerol content account for the improvements in insulin sensitivity after weight loss81 and therapy with thiazolidinediones.133”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“Though no reductions in the concentration of intramyocellular triglyceride were noted in this study, rosiglitazone improved insulin-mediated whole-body glucose disposal, consistent with improvements in muscle insulin sensitivity.”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [133]
In the citing paper
“The TZDs improve insulin resistance by increasing glucose disposal in muscle and decreasing hepatic glucose output.26”
From A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis (2004) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Self-citationDENSITOMETRIC ANALYSIS OF BODY COMPOSITION: REVISION OF SOME QUANTITATIVE ASSUMPTIONS*
Brožek, J., Grande, F., Anderson, J. T., & Keys, A. B. (1963) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1963.tb17079.x · Cited by 2,263
Mechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539
Self-citationDresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Self-citationGriffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Self-citationKrssak, M., Falk Petersen, K., Dresner, A., DiPietro, L., Vogel, S. M., Rothman, D. L., Shulman, G. I., & Roden, M. (1999) · Diabetologia · doi:10.1007/s001250051123 · Cited by 1,264
Self-citation
Cited by
Sorted by citations
Items 401–500 of 643
Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study
Dhaliwal, R., Shepherd, J., ghormli, L. K. E., Copeland, K. C., Geffner, M. E., HIGGINS, J. A., Levitsky, L. L., Nadeau, K. J., Weinstock, R. S., & White, N. H. (2019) · Diabetes Care · doi:10.2337/dc18-1935 · Cited by 21
Furukawa, H., Mawatari, K., Koyama, K., Yasui, S., Morizumi, R., Shimohata, T., Harada, N., Takahashi, A., & Nakaya, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.008 · Cited by 21
Trivedi, M. V., Marwaha, A., & Lokhandwala, M. F. (2004) · Hypertension · doi:10.1161/01.hyp.0000111587.51185.fe · Cited by 20
Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
Shao, Y., Chen, S., Liu, H., & Liu, J. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00748-x · Cited by 20
Djaouti, L., Jourdan, T., Demizieux, L., Chevrot, M., Gresti, J., Vergès, B. L., & Degrace, P. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1081 · Cited by 21
Leow, S.-S., Bolsinger, J., Prończuk, A., Hayes, K. C., & Sambanthamurthi, R. (2016) · Genes & Nutrition · doi:10.1186/s12263-016-0545-z · Cited by 19
Hao, Y., Tong, Y., Guo, Y., Lang, X., Huang, X., Xie, X., Guan, Y., & Li, Z. (2021) · Pharmacopsychiatry · doi:10.1055/a-1351-0566 · Cited by 21
NAFLD as the metabolic hallmark of obesity
Rojano‐Toimil, A., Sena, E., Manzano-Núñez, R., Pericàs, J. M., & Ciudin, A. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03139-x · Cited by 22
Rosiglitazone Inhibits Early Stage of Glucolipotoxicity-Induced Beta-Cell Apoptosis
Han, S. J., Kang, E. S., Hur, K. Y., Kim, H. J., Kim, S. H., Yun, C., Choi, S., Ahn, C. W., Soo, B., KANG, Y. Y., et al. (2008) · Hormone Research in Paediatrics · doi:10.1159/000137662 · Cited by 19
BMP‐TAK1 (MAP3K7) Induces Adipocyte Differentiation Through PPARγ Signaling
Zhang, Y., O’Keefe, R. J., & Jonason, J. H. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25626 · Cited by 19
Goldstein, B. J., Weissman, P. N., Wooddell, M. J., Waterhouse, B. R., & Cobitz, A. R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115720 · Cited by 19
Nadeau, K. J., Ehlers, L. B., Aguirre, L. E., Reusch, J. E. B., & Draznin, B. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00696.x · Cited by 19
Thiazolidinediones and Insulin
Huang, A., & Raskin, P. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504040-00002 · Cited by 19
Miyazaki, Y., De Filippis, E., Bajaj, M., Wajcberg, E., Glass, L., Triplitt, C., Cersosimo, E., Mandarino, L. J., & Defronzo, R. A. (2005) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514050050010601 · Cited by 18
Graham, A. D., Pandey, R., Tsancheva, V. S., Candeo, A., Botchway, S. W., Allan, A. J., Teboul, L., Madi, K., Babra, T. S., Zolkiewski, L., et al. (2019) · Biofabrication · doi:10.1088/1758-5090/ab56fe · Cited by 18
Berthiaume, M., Laplante, M., Festuccia, W. T., Berger, J. P., Thieringer, R., & Deshaies, Y. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.33 · Cited by 18
Kalderon, B., Mayorek, N., Ben-Yacov, L., & Bar‐Tana, J. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00368.2002 · Cited by 18
Adipose Tissue in Health and Disease
Leff, T., & Granneman, J. G. (2010) · Wiley eBooks · doi:10.1002/9783527629527 · Cited by 19
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes
Basu, R., Basu, A., Chandramouli, V., Norby, B., Dicke, B. A., Shah, P. J., Cohen, O., Landau, B. R., & Rizza, R. A. (2008) · Diabetologia · doi:10.1007/s00125-008-1138-1 · Cited by 17
New developments in type 2 diabetes mellitus: Combination therapy with a thiazolidinedione
Braunstein, S. N. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80195-9 · Cited by 18
Thiazolidinediones for the Therapeutic Management of Polycystic Ovary Syndrome
Elkind-Hirsch, K. E. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605030-00005 · Cited by 18
Feldt, T., Oette, M., Kroidl, A., Göbels, K., Fritzen, R., Kambergs, J., Kappert, G., Vogt, C., Wettstein, M., & Häussinger, D. (2006) · Infection · doi:10.1007/s15010-006-5022-y · Cited by 18
PPAR agonists in health and disease: a pathophysiologic and clinical overview
Mudaliar, S. R. D., & Henry, R. R. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200208000-00002 · Cited by 18
Nam, J. S., Nam, J. Y., Yoo, J. S., Cho, M., Park, J. S., Ahn, C. W., Cha, B. S., Lee, E. J., Lim, S.-K., Kim, K. R., et al. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02897.x · Cited by 17
Renin-angiotensin system activation in renal adipogenesis
Sui, Y., Zhao, H., Fan, R., Guan, J. Z., He, L., Lee, H. M., Chan, J. C. N., & Tong, P. C. Y. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00445.2009 · Cited by 17
Wilson, R. A., Arivazhagan, L., Ruiz, H. H., Zhou, B., Qian, K., Manigrasso, M. B., Bernadin, R., Mangar, K., Shekhtman, A. G., Li, H., et al. (2023) · Obesity · doi:10.1002/oby.23774 · Cited by 16
Pumprla, J., Howorka, K., Kolackova, Z., & Sovová, E. (2015) · F1000Research · doi:10.12688/f1000research.5708.1 · Cited by 17
Synthesis of PPAR-γ Activators Inspired by the Marine Natural Product, Paecilocin A
Xiao, B., Su, M., Kim, E. S., Hong, J., Chung, H. Y., Kim, H. S., Yin, J., & Jung, J. H. (2014) · Marine Drugs · doi:10.3390/md12020926 · Cited by 16
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes
Esther Phielix, E., Brehm, A., Bernroider, E., Krššák, M., Anderwald, C. H., Krebs, M., Schmid, A. I., Nowotny, P., & Roden, M. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12112 · Cited by 16
Metabolic effects of muraglitazar in type 2 diabetic subjects
Fernandez, M., Gastaldelli, A., Triplitt, C. L., Hardies, J., Casolaro, A., Petz, R., Tantiwong, P., Musi, N., Cersósimo, E., Ferrannini, E., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01429.x · Cited by 16
Chen, X., Feng, Y., Yang, W., Shu, G., Jiang, Q., & Wang, X. Q. (2013) · Asian-Australasian Journal of Animal Sciences · doi:10.5713/ajas.2012.12722 · Cited by 16
Courtney, C. H., & Olefsky, J. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-72204-7_10 · Cited by 22
Jung, U. J., Baek, N., Chung, H., Jeong, T., Lee, K., Lee, M., & Choi, M. (2009) · Journal of Medicinal Food · doi:10.1089/jmf.2009.0039 · Cited by 16
Insulin Resistance: Causes and Consequences
Bloomgarden, Z. T. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(04)65001-x · Cited by 16
Pharmacologic management of nonalcoholic fatty liver disease
Harrison, S. A., & Neuschwander‐Tetri, B. A. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.011 · Cited by 16
Hung, Y.-J., Hsieh, C.-H., Pei, D., Kuo, S.-W., Lee, J., Wu, L.-Y., He, C.-T., Lee, C.-H., Fan, S., & Sheu, W. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02178.x · Cited by 18
Obesity, insulin resistance, Type 2 diabetes and free fatty acids
Boden, G. H. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.4.499 · Cited by 16
Tsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
Mai, K., Andres, J., Bobbert, T., Aßmann, A., Biedasek, K., Diederich, S., Graham, I. A., Larson, T. R., Pfeiffer, A. F. H., & Spranger, J. (2011) · Metabolism · doi:10.1016/j.metabol.2011.05.018 · Cited by 15
Glass, L. C., Cusi, K. J., Berria, R., Petz, R., Cersósimo, E., DeFronzo, R. A., & Gastaldelli, A. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03811.x · Cited by 15
L'AMPK : une enzyme au coeur de l'homéostasie énergétique
Daval, M., Ferré, P., & Foufelle, F. (2006) · Journal de la Société de Biologie · doi:10.1051/jbio:2006013 · Cited by 15
Role of the Adipocyte in Metabolism and Endocrine Function
Ravussin, É., & Smith, S. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00036-6 · Cited by 16
Smiley, D. D., & Umpierrez, G. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.9.1353 · Cited by 15
Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice
Liu, J. Y., Wang, D., Xie, Z., Ding, L., Li, S., Ma, X.-M., Liu, J., Ren, J., Xiao, C., Yang, C., et al. (2023) · Biomolecules · doi:10.3390/biom13081199 · Cited by 14
Moyle, G. J., & Sutinen, J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15521-9 · Cited by 14
Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents
Dominguez, L. J., & Sowers, J. R. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0083-3 · Cited by 14
Rosiglitazone plus metformin: combination therapy for Type 2 diabetes
Prato, S. D., & Volpe, L. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.6.1411 · Cited by 14
Guichelaar, M. M. J., & Charlton, M. (2014) · Hepatology · doi:10.1002/hep.27058 · Cited by 14
Application of Microdialysis in Clinical Pharmacology
Höcht, C., Opezzo, J. A. W., Bramuglia, G. F., & Taira, C. A. (2006) · Current Clinical Pharmacology · doi:10.2174/157488406776872587 · Cited by 13
Ortmeyer, H. K., Sajan, M. P., Miura, A., Kanoh, Y., Rivas, J., Li, Y., Standaert, M. L., Ryan, A. S., Bodkin, N. L., Farese, R. V., et al. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3234 · Cited by 13
Insulin Resistance, Hepatic Lipid and Adipose Tissue Distribution in HIV-Infected Men
He, Q. W., Engelson, E. S., Ionescu, G. O., Glesby, M. J., Albu, J., & Kotler, D. P. (2008) · Antiviral Therapy · doi:10.1177/135965350801300309 · Cited by 13
Zhang, F., Sjöholm, Å., & Zhang, Q. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.103 · Cited by 13
Rosak, C., Standl, E., Reblin, T., Stammer, H., & Seidel, D. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01092.x · Cited by 12
Yousefi, A. R., Kohram, H., Shahneh, A. Z., Zamiri, M. J., & Fouladi-Nashta, A. A. (2016) · Theriogenology · doi:10.1016/j.theriogenology.2016.01.015 · Cited by 12
Effects of pioglitazone in familial combined hyperlipidaemia
Abbink, E. J., Graaf, J. D., de Haan, J. H., Heerschap, A., Stalenhoef, A. F. H., & Tack, C. J. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01579.x · Cited by 12
For personal use. Only reproduce with permission from The Lancet.
Jung, J. H., Min, P., Moon, Y. J., Heum, W., & Shim (2004) · Cited by 12
Non‐Alcoholic Fatty Liver Disease
Day, C. (2004) · doi:10.1002/9780470987025.ch26 · Cited by 12
Lee, M. Y., Koh, J. H., Nam, S. M., Jung, P. M., Sung, J. K., Kim, S., Shin, J. Y., Shin, Y. G., & Chung, C. H. (2008) · Yonsei Medical Journal · doi:10.3349/ymj.2008.49.6.901 · Cited by 10
Combination Therapy in Type 2 Diabetes
Bajaj, M., & DeFronzo, R. A. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0613 · Cited by 11
The Molecular Basis of PPAR Function
Barak, Y., & Lee, C. (2010) · PPAR Research · doi:10.1155/2010/510530 · Cited by 11
Effets cardiovasculaires de la rosiglitazone
Feuvre, C. L. (2004) · La Presse Médicale · doi:10.1016/s0755-4982(04)98730-1 · Cited by 11
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 10
Godoy‐Matos, A. F., Bahia, L., Domingues, R. C., Tambascia, M. A., Geloneze, B., Kraemer‐Aguiar, L. G., & Bouskela, E. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02868.x · Cited by 10
Jong, K. A. D., Ehret, S., Heeren, J., & Nikolaev, V. O. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112433 · Cited by 10
Bouter, S. L., Rodriguez, M., Guigal, N., Courtade-Gaïani, S., Xuereb, L., de Montrion, C., Croixmarie, V., Umbdenstock, T., Boursier-Neyret, C., Lonchampt, M., et al. (2010) · PPAR Research · doi:10.1155/2010/679184 · Cited by 10
Lipotoxicity in Obesity: Benefit of Olive Oil
Saad, E., Sbeit, W., Luai, A., Massad, B., & Assy, N. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-48382-5_26 · Cited by 11
Effects of rosiglitazone on intramyocellular lipid accumulation in Psammomys obesus
Molero, J. C., Lee, S., Leizerman, I., Chajut, A., Cooper, A., & Walder, K. R. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.10.002 · Cited by 10
Bakhtiyari, S., Zaherara, M., Haghani, K., Khatami, M., & Rashidinejad, A. (2019) · Lipids · doi:10.1002/lipd.12133 · Cited by 10
Liu, X., Cai, S., Yi, J., & Chu, C. (2023) · Nutrients · doi:10.3390/nu15184080 · Cited by 9
Therapeutic agents for Alzheimer’s disease: a critical appraisal
Weinstock, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1484615 · Cited by 9
Luo, Y.-C., Huang, S., Pathak, N., Chuang, Y., & Yang, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119650 · Cited by 9
Karimfar, M. H., Haghani, K., Babakhani, A., & Bakhtiyari, S. (2015) · Lipids · doi:10.1007/s11745-015-4016-x · Cited by 9
Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus
Hefetz, S., Ziv, E., Jörns, A., Lenzen, S., & Shafrir, E. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.583 · Cited by 9
Locating the source of hyperglycemia: Liver versus muscle
Yu, H., Zhou, D., Jia, W., & Guo, Z. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00170.x · Cited by 9
Muscle Type‐Dependent Responses to Insulin in Intramyocellular Triglyceride Turnover in Obese Rats
Guo, Z., & Zhou, L. (2005) · Obesity Research · doi:10.1038/oby.2005.258 · Cited by 9
Cell Rejuvenation with Thiazolidinediones
Bell, D. S. H. (2003) · Cited by 9
Insulin Resistance, Adipocyte Biology, and Thiazolidinediones: A Review
Tarçın, Ö., Bajaj, M., & Akalın, S. (2007) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2007.0001 · Cited by 9
Ortmeyer, H. K., Adall, Y., Marciani, K. R., Katsiaras, A., Ryan, A. S., Bodkin, N. L., & HANSEN, B. C. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00692.2004 · Cited by 9
Glintborg, D., Hermann, A. P., Rasmussen, L. M., & Andersen, M. (2013) · PubMed · doi:10.3275/8767 · Cited by 9
Boden, G. H. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-141-3_4 · Cited by 8
Sinnathamby, E. S., Urban, B., Clark, R. A., Roberts, L. T., Witt, A. J. D., Wenger, D. M., Mouhaffel, A., Willett, O., Ahmadzadeh, S., Shekoohi, S., et al. (2024) · Cureus · doi:10.7759/cureus.53400 · Cited by 8
Kavak, S., Ayaz, L., & Emre, M. (2012) · Experimental Diabetes Research · doi:10.1155/2012/905683 · Cited by 8
Effects of tomato ketchup and tomato paste extract on hepatic lipid accumulation and adipogenesis
Jeong, J. H., Lee, H. L., Park, H. J., Yoon, Y. E., Shin, J., Jeong, M., Park, S. H., Kim, D., Han, S. W., Kang, C., et al. (2023) · Food Science and Biotechnology · doi:10.1007/s10068-023-01244-x · Cited by 8
van Tits, L. J. H., Oral, E. A., Sweep, F. C. G. J., Smits, P., Stalenhoef, A. F. H., & Tack, C. J. (2005) · PubMed · Cited by 8
The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy
Wyne, K. L. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00522.x · Cited by 8
Type 2 diabetes mellitus: A disease of the governance of the glucose-insulin system
Trombetta, M., Boselli, L., Cretti, A., Cali, A. M. G., Vettore, M., Caruso, B., Dorizzi, R. M., Avogaro, A., Muggeo, M., Bonora, E., et al. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.05.006 · Cited by 8
Coletta, D. K., Fernandez, M., Cersósimo, E., Gastaldelli, A., Musi, N., & DeFronzo, R. A. (2014) · Diabetic Medicine · doi:10.1111/dme.12664 · Cited by 8
Zhyzhneuskaya, S. V., & Taylor, R. (2017) · Endocrinology · doi:10.1007/978-3-319-47685-8_21-1 · Cited by 8
Krag, M. B., Nielsen, S., Guo, Z., Pedersen, S. B., Schmitz, O., Christiansen, J. S., & Jørgensen, J. O. L. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03231.x · Cited by 8
Shargorodsky, M., Michaelova, K., Boaz, M., Gavish, D., & Zimlichman, R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02231.x · Cited by 8
Is the metabolic syndrome a real clinical entity and should it receive drug treatment?
Darsow, T., Kendall, D. M., & Maggs, D. G. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0006-y · Cited by 8
Insulin interacts with PPARγ agonists to promote bovine adipocyte differentiation
Guo, P., Yao, X., Xu, Y., Jin, X., Li, Q., Yan, C., Kim, N., & Li, X. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106848 · Cited by 7
(2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/978160805361211201010039 · Cited by 7
Hendley, M. A., Isely, C., Murphy, K. P., Hall, H. E., Annamalai, P., & Gower, R. M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00562 · Cited by 8
Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Jeong, S., Shin, W.-Y., & Oh, Y. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1150360 · Cited by 7
Wu, L., Cui, J., Zhao, C., Wang, Z., Lu, J., Li, S., Jia, J., Xiao, H., & Zhang, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00323 · Cited by 7
Kim, J., Heo, J.-S., Choi, J., Kim, G., & Sohn, K. (2015) · Journal of Life Science · doi:10.5352/jls.2015.25.10.1081 · Cited by 7
Place des thiazolidinediones dans le traitement du diabète de type 2
Blickle, J. (2004) · La Presse Médicale · doi:10.1016/s0755-4982(04)98833-1 · Cited by 7
La stéatohépatite non alcoolique
Ratziu, V., Tahiri, M., & Bonyhay, L. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81735-4 · Cited by 16
Zukünftige Angriffspunkte für die Therapie des Typ-2-Diabetes
Stingl, H., & Roden, M. (2004) · Wiener klinische Wochenschrift · doi:10.1007/bf03041051 · Cited by 7
Metadata
- Authors
- Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F.
- Affiliations
- Yale University (US)
- Howard Hughes Medical Institute (US)
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2002-03-01
- Volume
- 51
- Issue
- 3
- Pages
- 797-802
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2995527
- OpenAlex
- W2100514340
- Cited by
- 647
- References
- 53
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 11 · 2023: 15 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 20 · 2018: 12 · 2017: 15 · 2016: 15 · 2015: 22 · 2014: 20 · 2013: 22 · 2012: 16
- FWCI
- 24.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Yale University
- Deutsches Krebsforschungszentrum
- U.S. Public Health Service
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01DK049230, R01 DK-49230, K23DK002734, P30DK045735)
- National Center for Research Resources (M01RR000125, M01 RR-00125)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- rosiglitazone, thiazolidinediones, type 2 diabetes, insulin sensitivity, hepatic triglyceride content, extramyocellular lipids, plasma fatty acids, hyperinsulinemic-euglycemic clamp, microdialysis, lipid redistribution
- MeSH terms
- Rosiglitazone, Adipose Tissue, Blood Glucose, Body Composition, Calorimetry, Indirect, Diabetes Mellitus, Type 2, Fatty Acids, Glycerol, Glycated Hemoglobin, Humans, Hyperinsulinism, Insulin, Kinetics, Lipids, Lipolysis, Liver, Middle Aged, Magnetic Resonance Spectroscopy, Oxidation-Reduction, Thiazoles, Triglycerides, Glucose Clamp Technique, Microdialysis, Adipocytes, Muscle, Skeletal, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
